Published study found a method designed for preserving forensic DNA outperformed other commonly used faecal preservation methods.
We are innovating to help humanity achieve some of its most inspiring medical advancements in the 21st century. Read about Microba’s progress, partnership news and latest discoveries.
Professor Hugenholtz will discuss approaches to using new tools and data in research and explain the different approaches to taxonomic classification.
Microba Community Profiler (MCP) outperforms existing profilers for accurate and comprehensive characterisation of the human gut microbiome.
Mark Capone to strengthen diagnostics platform with 35-year career in life sciences and molecular diagnostics.
Microba Life Sciences, is empowering global consumer goods company Unilever to explore links between sleep and the human gut.
Microba’s commitment to developing life-changing therapeutics derived from the gut microbiome will add a valuable voice to MTIG’s mission.
A/Prof Krause will discuss the human-first, data-driven approach to therapeutic discovery that Microba employs in their IBD therapeutic program.
The partnership's first clinical trial will determine if a new treatment can restore beneficial gut microbiome species and improve symptoms.
Bringing Microba’s world-leading metagenomic sequencing and bioinformatics together with Holobiome’s promising microbiome therapeutic pipeline.